The weight loss pill could become a best in class drug according to the CEO

Novo Nordisk says it has agreed to buy Cardior Pharmaceuticals for up to 1.03 billion euros. The deal will strengthen the company's cardiovascular pipeline. The Danish drugmaker said it will buy the drugmaker's Cardior for $1.1 billion.

Lars Fruergaard Jørgensen's remarks came one day after Novo Nordisk impressed investors with early-stage trial data on amycretin. The company's CEO says experimental weight loss pill could become a best in class drug. The drug could be a best-in-class drug, he says.

Wegovy obesity drug maker Novo Nordisk surpassed Tesla in market value Thursday. New early trial data showed positive results for its new experimental weight loss pill. Novo's market cap surpasses Tesla on new obesity pill trial data. Wegovys drug maker is also a leading manufacturer in the world of obesity drugs.

Novo Nordisk shares jump 5% on Thursday morning after positive early trial data for weight loss drug. Eli Lilly dips on Thursday as company reports positive early data for new weight-loss drug. Danish pharmaceutical giant also reports positive results for new drug, which is being tested in trials on weight loss drugs.